Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Decipher LabsBOM:524752 -4.70%57 Quick Ratio is 5.21 as of Mar. 2026, which is 89% above its 10-year median of 2.75. GuruFocus rates BOM:524752 with a GF Score™ of 57/100 and a GF Value™ of ₹6.34 (Fairly Valued). The stock has 3 warning signs investors should review. Among 997 Drug Manufacturers companies, Decipher Labs ranks better than 89.47% on this metric.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Decipher Labs's quick ratio for the quarter that ended in Mar. 2026 was 5.21.
Decipher Labs has a quick ratio of 5.21. It generally indicates good short-term financial strength.
The historical rank and industry rank for Decipher Labs's Quick Ratio or its related term are showing as below:
BOM:524752'
s Quick Ratio Range Over the Past 10 Years
Min: 0.48 Med: 2.75 Max: 7.24
Current: 5.21
During the past 13 years, Decipher Labs's highest Quick Ratio was 7.24. The lowest was 0.48. And the median was 2.75.
BOM:524752's Quick Ratio is ranked better than 89.47% of 997
companies
in the Drug Manufacturers industry
Industry Median: 1.45
vs BOM:524752: 5.21
Decipher Labs (BOM:524752) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Decipher Labs Quick Ratio Related Terms
Decipher Labs Quick Ratio Historical Data
* Premium members only.
The historical data trend for Decipher Labs's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Decipher Labs's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Decipher Labs Quick Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Decipher Labs's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Decipher Labs's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Decipher Labs's Quick Ratio for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Decipher Labs (BOM:524752) has a Quick Ratio of 5.21 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Decipher Labs and its competitors. This is 89% above median its historical median of 2.75. Over the past decade, Decipher Labs' Quick Ratio has ranged from 0.48 to 7.24. According to the industry distribution chart, Decipher Labs ranks #105 out of 997 companies in the Drug Manufacturers industry, placing it in the top 10.5%.
Is Decipher Labs' Quick Ratio too high?
Decipher Labs' current Quick Ratio of 5.21 is 89% above median its 10-year median of 2.75. Over the past 10 years, this metric has ranged from a low of 0.48 to a high of 7.24. The Drug Manufacturers industry median Quick Ratio is 1.45. Decipher Labs' value of 5.21 is 259.3% above this industry median. Based on the distribution chart, Decipher Labs ranks #105 out of 997 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Decipher Labs has a GF Score™ of 57/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Decipher Labs' Quick Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Decipher Labs ranks #105 out of 997 companies for Quick Ratio. This places Decipher Labs in the top 11% of its industry — outperforming the majority of peers. The industry median Quick Ratio is 1.45. Decipher Labs' value of 5.21 is 259.3% above this benchmark. Historically, Decipher Labs' own Quick Ratio has ranged from 0.48 to 7.24 over the past decade. While the company's 10-year median is 2.75 vs. the industry median of 1.45, Decipher Labs has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Drug Manufacturers company?
The median Quick Ratio among Drug Manufacturers companies is 1.45, based on 997 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Decipher Labs's current Quick Ratio of 5.21 is 259.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Decipher Labs and its competitors. For the Drug Manufacturers industry, the median Quick Ratio is 1.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Decipher Labs's current Quick Ratio is 5.21, which is 89% above median its own 10-year median of 2.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Decipher Labs stock overvalued right now?
Based on GuruFocus' analysis, Decipher Labs (BOM:524752) is currently considered Fairly Valued. The stock's GF Value™ is ₹6.34, compared to a current price of ₹6.29 — trading 0.8% below its estimated fair value. The current Quick Ratio is 5.21, which is 89% above median its 10-year median of 2.75 and 259.3% above the Drug Manufacturers industry median of 1.45. Decipher Labs' overall GF Score™ is 57/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Decipher Labs (BOM:524752), the current Quick Ratio is 5.21 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Decipher Labs (BOM:524752) Overvalued in 2026?
Based on GuruFocus' analysis, Decipher Labs stock appears to be undervalued.
The current stock price of ₹6.29 is trading 0.8% below its estimated GF Value™ of ₹6.34.
GuruFocus considers Decipher Labs to be Fairly Valued.
Key valuation signals for BOM:524752:
Quick Ratio: 5.21 (89% above median its 10-year median of 2.75)
GF Value™: ₹6.34 vs. price of ₹6.29 (0.8% below fair value)
Industry Position: 259.3% above the Drug Manufacturers median (#105 of 997)
No single metric tells the full story. See the BOM:524752 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Decipher Labs Ltd deals in the trading and manufacturing of Pharmaceutical drugs and allied products and services, and also offers services and key solutions in the Information Technology industry. It is involved in the manufacturing and marketing of its branded pharmaceutical products, and also provides drug development and manufacturing services to various formulators, manufacturers, and Research and Development agencies for their bulk needs. The group's IT Consultancy offerings include Technology Integration and Systems Consulting, Software Development Consulting, and Management of IT projects. Its reportable operating segments are: Pharmaceutical, which generates the maximum revenue, and IT Consultancy Services. Geographically, the group derives its key revenue from India.
57GF Score
Get the complete analysis for BOM:524752
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:524752 has been successfully added to your 
